Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Dose-Escalation Study of the Safety of Adoptively Transferred Autologous CD8+ T Lymphocytes Targeting HPV-16 E6/E7, HPV-18 E6/E7 and Survivin in Patients With Relapsed or Refractory HPV-related Oropharyngeal Cancers

NCT05582590 is registered in ClinicalTrials.gov with NexImmune Inc. as lead sponsor.

NCT NCT05582590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05582590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Dose-Escalation Study of the Safety of Adoptively Transferred Autologous CD8+ T Lymphocytes Targeting HPV-16 E6/E7, HPV-18 E6/E7 and Survivin in Patients With Relapsed or Refractory HPV-related Oropharyngeal Cancers
Lead sponsor
NexImmune Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 31, 2025
Completion date
August 25, 2027
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck cancer metastatic, head and neck squamous cell carcinoma, hpv-related mucosal head and neck squamous cell carcinoma, hpv-related squamous cell carcinoma, human papilloma virus, oropharyngeal cancer, oropharyngeal cancer, metastatic, oropharyngeal squamous cell carcinoma, refractory oropharyngeal squamous cell carcinoma, relapsed oropharyngeal scc